Grenoble Alpes University Hospital, Addictovigilance Dept, Grenoble, France; Grenoble Alpes University, HP2 Lab, Inserm U1300, Grenoble, France.
Grenoble Alpes University Hospital, Pharmacology Pharmacogenetics & Toxicology Lab, Grenoble, France; Grenoble Alpes University Hospital, Clinical Forensic Medicine Dept, Grenoble, France.
Public Health. 2024 Nov;236:381-385. doi: 10.1016/j.puhe.2024.08.019. Epub 2024 Sep 19.
To describe analgesic-related deaths in France and report trends over a 10-year period.
The DTA ("Décès Toxiques par Antalgiques") register is a French database of analgesic-related deaths among people without a history of drug abuse, reported by forensic toxicology experts.
We included analgesic-related deaths occurring from January 2013 to December 2022 in France. Subject demographic characteristics and medical history, forensic autopsy findings, and toxicology reports were evaluated.
Among the 1036 deceased individuals (mean [SD] age, 48.3 [15.6] years), there were slightly more women than men (M:F sex ratio, 0.89:1). Over the entire study period, tramadol was the leading cause of death, ahead of morphine. A relative increase in oxycodone-related mortality was observed (from 6.8% in 2013 to 21.1% in 2022) compared to a progressive decrease in tramadol, morphine, and codeine-related deaths (from 43.2%, 31.1% and 24.3% in 2013 to 37.5%, 26.6% and 20.3% in 2022, respectively). However, no statistically significant variations were found (Chi-squared tests of homogeneity). Other analgesics (buprenorphine, dihydrocodeine, fentanyl, gabapentin, ketamine, methadone, nefopam, and pregabalin) were also implicated in deaths, but with low and stable rates over the period studied.
In France, no increase in fentanyl-related deaths and only a non-significant increase in oxycodone-related deaths were observed over the period 2013-2022. Tramadol was the leading cause of analgesic-related deaths throughout this period. Although close monitoring is still required, particularly for oxycodone, our data do not support the hypothesis of an opioid crisis in France.
描述法国的镇痛药相关死亡情况,并报告 10 年来的趋势。
DTA(“因镇痛药导致的毒性死亡”)登记册是一个法国数据库,记录了无药物滥用史的人群中与镇痛药相关的死亡情况,由法医毒理学专家报告。
我们纳入了 2013 年 1 月至 2022 年 12 月期间法国发生的镇痛药相关死亡事件。评估了死者的人口统计学特征和病史、法医尸检结果和毒理学报告。
在 1036 名死者中(平均[标准差]年龄,48.3[15.6]岁),女性略多于男性(男女比为 0.89:1)。在整个研究期间,曲马多是主要的死亡原因,其次是吗啡。与曲马多、吗啡和可待因相关的死亡呈逐渐下降趋势相比,羟考酮相关的死亡率呈相对上升趋势(从 2013 年的 6.8%上升至 2022 年的 21.1%)(2013 年分别为 43.2%、31.1%和 24.3%,2022 年分别为 37.5%、26.6%和 20.3%)。然而,没有发现统计学上的显著变化(同质性卡方检验)。其他镇痛药(丁丙诺啡、二氢可待因、芬太尼、加巴喷丁、氯胺酮、美沙酮、奈福泮和普瑞巴林)也与死亡有关,但在研究期间的发生率较低且稳定。
在法国,2013-2022 年间,芬太尼相关死亡人数没有增加,羟考酮相关死亡人数仅略有增加。曲马多是整个时期镇痛药相关死亡的主要原因。尽管仍需密切监测,特别是对羟考酮,但我们的数据不支持法国阿片类药物危机的假设。